Ultrasound lesions in temporal and axillary arteries and relapse risk in giant cell arteritis.
Official title: Association of Ultrasonographic Temporal Artery Lesions and Relapse in Patients With Giant Cell Arteritis
Run by University Hospital, Brest · NCT06894602 · Data updated 2026-11-12
We will test whether lesions seen on ultrasound of the temporal and axillary arteries can predict relapse in people with giant cell arteritis.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University Hospital, Brest Academic / other |
| Locations | 2 sites (Brest and 1 other locations) |
| Status | Recruiting |
| Started | August 5, 2025 |
| Main results expected | August 1, 2028 |
| Study ends | August 1, 2028 |
| Registry record updated | March 20, 2026 |
| Trial ID | NCT06894602 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults who meet the 2022 ACR criteria for giant cell arteritis, can give informed consent, and receive care at the participating centers in Brest or Quimper are ideal candidates.
✕Probably not a fit
Patients who cannot consent (for example, those under guardianship), are not affiliated to the French Social Security system, or cannot access the participating centers are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, bicentric longitudinal observational study enrolling 100 patients with giant cell arteritis at two French university hospitals. Participants will have three routine visits that include clinical assessment, blood tests, and ultrasound of the temporal and axillary arteries using the OGUS scoring system. Ultrasound examinations will be performed as part of standard care and will not be blinded to clinicians, and the study will analyze whether ultrasound lesion patterns or OGUS scores are associated with clinico-biological relapse. No interventional procedures or additional costs are required and follow-up imaging is integrated into routine care.
Why it matters
Potential benefit: If successful, routine ultrasound findings and OGUS scores could help doctors predict relapses earlier and tailor monitoring or treatment for people with GCA.
How similar studies have gone: Ultrasound is an established diagnostic and monitoring tool in GCA and the OGUS score exists, but longitudinal evidence directly linking specific ultrasound lesions to relapse is limited and not yet definitive.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Major patient * Patients meeting ACR 2022 criteria for giant cell arteritis. * No opposition expressed Exclusion Criteria: * Patients unable to understand the protocol, under guardianship or curatorship. * Patients not affiliated to the French Social Security system.
Where it's running
-
Chu Brest
Brest, France Recruiting -
Ch Quimper
Quimper, France Recruiting
Study contacts
- Study coordinator: Sandrine Pr JOUSSE-JOULIN
- Email: sandrine.jousse-joulin@chu-brest.fr
- Phone: 298347267
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How optic nerve swelling changes after starting steroids in giant cell arteritis
This study tests how quickly the optic nerve sheath swelling decreases after starting glucocorticoids in people with newly diagnosed giant cell arteritis.
-
Precision care for giant cell arteritis and polymyalgia rheumatica
This long-term observational project will follow adults with giant cell arteritis or polymyalgia rheumatica to see if regular imaging, eye exams, blood tests, and immune cell profiling can better predict aortic complications and steroid side effects over 5–10 years.
-
Understanding how Giant Cell Arteritis affects vision
This study is trying to understand how Giant Cell Arteritis affects vision in adults by comparing eye health in those with GCA-related vision problems to those with other causes of vision loss.
-
Understanding biomarkers in giant cell arteritis and polymyalgia rheumatica
This study is trying to find specific markers in the blood of people newly diagnosed with giant cell arteritis and polymyalgia rheumatica to help doctors understand their disease better and create personalized treatment plans.
-
Investigating a new imaging tracer for diagnosing giant cell arteritis
This study is testing a new imaging method called AzaFol-PET/CT to see if it can better diagnose giant cell arteritis in people aged 50 and older compared to the current standard method.
-
Exploring how the gut microbiome affects giant cell arteritis
This study looks at how the bacteria in the gut might affect people with giant cell arteritis to see if they can find clues for better treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.